stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Revenue growth
Alnylam Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 56.2%, down 9.0 percentage points from fiscal 2025 (65.2%). Over the past ten years it has ranged from −18.7% (fiscal 2015) to 193.4% (fiscal 2019); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 65.2% | 42.22 |
| FY2024 | 23.0% | (53.26) |
| FY2023 | 76.2% | 53.35 |
| FY2022 | 22.9% | (48.43) |
| FY2021 | 71.3% | (52.97) |
| FY2020 | 124.3% | (69.08) |
| FY2019 | 193.4% | 210.05 |
| FY2018 | −16.7% | (107.35) |
| FY2017 | 90.7% | 75.91 |
| FY2016 | 14.8% | 33.47 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 16.7% | (50.12) |
| Jun 2026 | 66.9% | (29.57) |
| Mar 2026 | 96.4% | 11.48 |
| Dec 2025 | 85.0% | (64.40) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 240.0% |
| BBIO BridgeBio Pharma, Inc. compare | 167.3% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| ALNY Alnylam Pharmaceuticals, Inc. | 56.2% |
| INCY Incyte Corporation compare | 24.9% |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.5% |
| EXEL Exelixis, Inc. compare | 9.12% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement